NYSE Euronext accueille ADOCIA sur son marché européen

Back

Paris, 20 February 2012– ADOCIA, a key player in regenerative medicine and treatment of chronic diseases, today celebrated its listing on NYSE Euronext in Paris.

Founded in 2005, ADOCIA designed and developed BioChaperone®, a proprietary technology platform that improves the therapeutic performance of proteins such as insulin and the growth factors used to treat diabetes and chronic wounds. The company has several promising products in its portfolio and is currently working in two development partnerships with pharmaceutical companies that rank among the very largest in the industry. It recently signed an exclusive worldwide license with a major company to develop an ultra-fast-acting insulin analogue, an agreement that involves milestone payments that could total as much as $166 million. ADOCIA is based in Lyon and has 49 employees, with 80% working in Research & Development.

ADOCIA (ticker code: ADOC) was listed through the admission to trading of 4,458,710 existing shares and 1,592,798 new shares issued under a Global Offering[1], including full exercise of the extension clause. The Global Offering raised a total of €25.3 million, which could rise to €29.1 million if the Over-allotment option is fully exercised.

The admission and issue price of ADOCIA shares was set at €15.88. Market capitalisation stood at around €96.1 million on the day of listing.

“We are delighted to welcome Lyon-based ADOCIA to NYSE Euronext in Paris. Lyon and its region are home to many chemical, pharmaceutical and biotechnology companies. Together they form a vibrant hub that is France’s premier market for life sciences and one of the largest in Europe,”said Marc Lefèvre, Head of European Coverage at NYSE Euronext.

“The stock exchange contributes to regional job creation, and there is no doubt that in recent years it has strengthened Lyon’s emergence as the second large employment hub in France,”he added. “I would like to congratulate ADOCIA on its successful public offering and also extend my warmest thanks to our local partners, with whom we have set up agreements and who help to offer businesses, particularly SMEs, the benefits of strong momentum for financial markets.”

Gérard Soula, CEO and cofounder of ADOCIA, said: “We are very pleased and proud to be the first company to finalise arrangements for funding this year through a listing on NYSE Euronext in Paris and to do so successfully. On behalf of ADOCIA, I would like to thank all the shareholders who have put their trust in us and who will henceforth accompany us in our growth. I would also like to wholeheartedly thank all our partners and our staff who have enabled us to successfully reach this major milestone. On the eve of this new phase in our development, we would like to reaffirm our strategic intention of making ADOCIA a leading international company in the domains of regenerative medicine and the treatment of diabetes, a strategy made possible by the support of all our new and historical shareholders.”



[1]The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.6 trillion in market capitalisation as of end December 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.